Breast Cancer Risk After Diagnostic Gene Sequencing

NACompletedINTERVENTIONAL
Enrollment

405

Participants

Timeline

Start Date

October 22, 2019

Primary Completion Date

August 27, 2021

Study Completion Date

March 3, 2022

Conditions
Genetic Predisposition to Disease
Interventions
GENETIC

BRIDGES gene panel testing

"The Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm-BOADICEAV5/PLUS predicts lifetime and age-specific breast cancer (BC) risks on the basis of family history, all known BC genes test-results, common single nucleotide polymorphisms (SNPs) combined in a PRS, and other non-genetic risk factors. This model is developed within the BRIDGES consortium."

GENETIC

Breast cancer risk polygenic risk score (PRS)

"The Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm-BOADICEAV5/PLUS predicts lifetime and age-specific breast cancer (BC) risks on the basis of family history, all known BC genes test-results, common single nucleotide polymorphisms (SNPs) combined in a PRS, and other non-genetic risk factors. This model is developed within the BRIDGES consortium."

BEHAVIORAL

Questionnaires

Self-administered questionnaires for counselees to evaluate Psychosocial Aspects of Hereditary Cancer (PAHC), Breast Cancer risk perception adequacy, risk communication within the family and cancer risk management choice,

Trial Locations (2)

50923

University Hospital of Cologne, Cologne

75005

Institut Curie, Paris

All Listed Sponsors
lead

Institut Curie

OTHER

NCT04145817 - Breast Cancer Risk After Diagnostic Gene Sequencing | Biotech Hunter | Biotech Hunter